Garuda - Garba Rujukan Digital

PENGARUH HIPERKOAGULASI TERHADAP MORTALITAS ASTROSITOMA PADA PEMANTAUAN 12 BULAN Among Wibowo; Tiara Aninditha; Henry Riyanto Sofyan; Rini Andriani
NEURONA Vol 37 No 1 (2019)
Publisher : PERDOSNI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52386/neurona.v37i1.96

EFFECT OF HYPERCOAGULABILITY TO ASTROCYTOMA MORTALITY WITHIN 12-MONTHS OF FOLLOW UPABSTRACTIntroduction: Astrocytoma is the most common primary brain tumor. Hypercoagulable state is one of brain tumor complications which can cause vein thromboembolism (VTE). Vein thromboembolism incidence is increased in astrocytoma patients. Hypercoagulable state in astrocytoma could lower patient’s survival.Aim: To investigate the effect of hypercoagulable state on mortality within 12 months of follow up in astrocytoma patients.Methods: This study design was retrospective cohort. This research data was taken from medical records in Cipto Mangunkusumo General Hospital and Dharmais Cancer Center Hospital on December 2017-February 2018. The subjects were adult astrocytoma patients who had histopathology and hemostasis examination. The variables investigated in this study were gender, age, prothrombin time (PT), activated partial thromboplastin time (aPTT), and D-dimer. Data processed descriptively and analytically using SPSS ver. 20 for Windows.Results: There were 49 subjects in this research. Around 30 (61.2%) subjects were men and 20 (40.8%) subjects aged >50 years old. High grade glioma was found in 39 (79.6%) subjects and hypercoagulable state was found in 34 (69.4%) subjects. There were 20 subjects deceased in 12-month follow-up. Subjects with hypercoagulable state had relative risk (RR) of 3.97 more susceptible to die in 12-month follow-up compared to control (p=0.009).Discussion: Hypercoagulation was a mortality risk factor in 12-month follow-up in patients with astrocytoma.Keywords: Astrocytoma, hypercoagulation, mortality within 12-months of follow upABSTRAKPendahuluan: Astrositoma merupakan tumor otak primer yang paling sering ditemukan. Salah satu komplikasi dari tumor otak adalah keadaan hiperkoagulasi. Keadaan hiperkoagulasi dapat menyebabkan tromboemboli vena. Insiden tromboemboli vena meningkat pada astrositoma. Keadaan hiperkoagulasi pada astrositoma dapat menurunkan kesintasan atau meningkatkan mortalitas pada pasien astrositoma.Tujuan: Mengetahui pengaruh hiperkoagulasi pada mortalitas pasien astrositoma dalam 12 bulan pemantauan.Metode: Penelitian kohort retrospektif terhadap pasien tumor otak jenis astrositoma yang dirawat oleh Divisi Neuroonkologi di RSUPN Dr. Cipto Mangunkusumo (RSCM) dan RS Pusat Kanker Dharmais (RSKD) pada bulan Desember 2017 hingga Februari 2018. Sumber data adalah data sekunder berupa rekam medis pasien dewasa yang telah memiliki hasil pemeriksaan histopatologis dan hemostasis. Variabel yang diambil dalam penelitian ini adalah jenis kelamin, usia, prothrombin time (PT), activated partial thromboplastin time (aPTT), dan D-dimer. Data diolah secara deskriptif dan analitik bivariat menggunakan SPSS ver. 20 for Windows.Hasil: Terdapat 49 subjek dalam penelitian ini yang mayoritas (61,2%) laki-laki, berusia <50 tahun (59,2%), dan memiliki jenis high grade gliomas (75,8%). Sebagian besar subjek mengalami hiperkoagulasi (69,4%) dan dalam kondisi hidup (59,2%) pada 12 bulan pascaperawatan. Subjek dengan hiperkoagulasi memiliki risiko relatif (RR) 3,97 kali lebih rentan mengalami kematian setelah 12 bulan dibandingkan kontrol (p=0,009).Diskusi: Hiperkoagulasi merupakan salah satu faktor risiko kematian dalam 12 bulan pada pasien astrositoma.Kata kunci: Astrositoma, hiperkoagulasi, mortalitas 12 bulan

PREVALENSI NYERI NEUROPATIK PADA PASIEN DENGAN NYERI KANKER DI RSUPN DR CIPTO MANGUNKUSUMO DAN PKN RS DHARMAIS Henry Riyanto Sofyan; Tiara Aninditha; Louis Kwandou; Jonathan Odilo; Rini Andriani
NEURONA Vol 37 No 3 (2020)
Publisher : PERDOSNI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52386/neurona.v37i3.160

Introduction: Cancer pain is one of the most common complications in cancer. As much as 30-50% of cancer patients experienced pain. Cancer pain patients have reported complaints of pain with a neuropathic component. Early diagnosis of neuropathic cancer pain has a clinical implication for patient management. However, the proportion of neuropathic cancer pain has not been studied in Indonesian population. Aim: The study was to get an overview of neuropathic pain prevalence among cancer pain patients in Cipto Mangunkusumo General Hospital and National Cancer Referral Dharmais Hospital. Methods: The design of this research was cross-sectional. The study was done in Cipto Mangunkusumo General Hospital and National Cancer Referral Dharmais Hospital in July-September 2019. The subjects in this research were adult cancer patients who consulted with the Department of Neurology. The data acquired were patient’s demography, cancer history, imaging, and pain assessment. PainDETECT questionnaire was employed to assess neuropathic pain. The data were processed and presented descriptively and analytically. Results: There were 57 subjects obtained in this research with average age of 45.91. As much as 31.6% subjects had neuropathic cancer pain. Breast cancer identified in 38.6% subjects. There were no differences of gender, age, cancer type, and pain intensity between subjects with and without neuropathic cancer pain. Radiating pain and subject with metastasis experienced neuropathic cancer pain more frequently. Discussion: The prevalence of neuropathic cancer pain in the Indonesian population is 31.6%. Radiating pain and patients with metastasis cancer tend to experienced neuropathic pain more frequently. Keywords: Cancer, Indonesia, neuropathic pain, prevalence

KESINTASAN PASIEN DENGAN METASTASIS LEPTOMENINGEAL YANG DIRAWAT DI BAGIAN NEUROLOGI RUMAH SAKIT KANKER DHARMAIS DAN RSUPN DR CIPTO MANGUNKUSUMO Elsa Susanti; Rini Andriani; Tiara Aninditha; Henry Riyanto Sofyan
NEURONA Vol 37 No 4 (2020)
Publisher : PERDOSNI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52386/neurona.v37i4.172

Introduction: Leptomeningeal metastasis is a condition where malignant cells spread to the leptomening and subarachnoid space. This is an emergency state with incident tends to increase each year. Prognosis is very poor and survival rate is only 10-15 weeks. Aim: To determine survival of leptomeningeal metastasis patients in Cancer Dharmais Hospital and Cipto Mangunkusumo Hospital. Methods: This is a retrospective cohort research based on medical records of leptomeningeal metastasis patients in Cancer Dharmais Hospital and Cipto Mangunkusumo Hospital from January 2018 to June 2019. Clinical examination, liquor cerebral examination, MRI, and histopathological of primary tumours were written. Subjects or family of the subjects were contacted to obtain information about subject’s wellbeing whether they’re still alive or dead. If they’re unreachable they will be excluded. Survival of each subject was determined based on how long the subject remain alive since being diagnosed with leptomeningeal metastasis until the end of observation, which is the end of the research. Results: Sixty two patients were included in the research, 21 were males and 41 were females. Headache was the most frequent symptoms found in the patients (46.8%) followed by cranial nerves deficits (45.2%). Median survival in this research was 13 weeks, no significant differences in survival from haematologic malignancy and solid tumor. Discussion: Median survival of leptomeningeal metastasis patients was 13 weeks, there was no statistically significant difference between survival of heamotologic malignancy and solid tumor. Median survival in leptomeningeal metastasis in this research remain poor regardless the origin of the metastasis. Keywords: Haematologic malignancy, leptomeningeal metastasis, solid tumor, survival

KARAKTERISTIK METASTASIS SISTEM SARAF PUSAT DARI KANKER PARU Tan Yosephine; Tiara Aninditha; Henry Riyanto Sofyan; Jonathan Odilo; Rini Andriani
NEURONA Vol 37 No 4 (2020)
Publisher : PERDOSNI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52386/neurona.v37i4.174

Introduction: As much as 40% of lung cancer patients will experience central nervous system (CNS) metastasis in the course of the disease. From those 40%, as much as 3-9% will experience leptomeningeal metastasis, but the clinical profile of CNS involvement in lung cancer has never been studied before in Indonesia. Aim: To give a description of CNS metastasis from lung cancer inCipto Mangunkusumo General Hospital and National Cancer Referral Dharmais Hospital. Methods: This is a cross-sectional study done in patients consulted to Neurology Department inCipto Mangunkusumo General Hospital and National Cancer Referral Dharmais Hospital in 2018. Inclusion cirteria is adult patients diagnosed with lung cancer based on histopathology with complete medical record to the extent of CT scan or Head MRI with contrast. Results: There were 48 subjects with median age of 57 (36-76) years, men were more than women (56.2% vs 44.8%) and 31.3% had history of smoking. The most frequent lung cancer type is non-small cell lung cancer (NSCLC) (93,8%). Neurological symptoms found were motoric deficits (62.5%), headache (43.8%), cognitive dysfunction (20.8%), and seizure (18.8%). Majority of subjects suffered from brain metastasis (93.8%) and 8.3% were leptomeningeal metastasis. Discussion: The majority of CNS metastasis were brain metastasis from NSCLC (93.8%) with main neurological deficits were motoric deficits (62.5%) and headache (43.8%). Keywords: Brain metastasis, lung cancer, non-small cell lung carcinoma

Title

Found 4 Documents
Search

Abstract

Abstract

Abstract

Abstract

Title Search

Found 4 Documents Search

Abstract

Abstract

Abstract

Abstract

Title

Found 4 Documents
Search